Want to join the conversation?
$PRGO, which competes with $AGN, said its Rx pipeline is strong and it expects greater than $5.5Bil in prescription brand sales over the next three years. The company has 25 ANDAs pending FDA approval, 5 Paragraph IV litigations, and 6 projects in clinical studies.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.